{"id":"ombrabulin-ave8062","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL572284","moleculeType":"Small molecule","molecularWeight":"402.45"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ombrabulin targets the tubulin-microtubule system in endothelial cells of tumor blood vessels, leading to rapid vascular collapse and tumor necrosis. Unlike conventional chemotherapy that primarily targets dividing cancer cells, vascular disrupting agents preferentially affect the abnormal vasculature supporting tumors, causing ischemic necrosis of the tumor core. This mechanism allows it to be effective against a broad range of solid tumors.","oneSentence":"Ombrabulin is a vascular disrupting agent that binds to tubulin and disrupts microtubule dynamics, causing selective destruction of tumor vasculature and tumor cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:10.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Ovarian cancer"},{"name":"Other solid tumors"}]},"trialDetails":[{"nctId":"NCT01332656","phase":"PHASE2","title":"Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Ovarian Cancer Recurrent","enrollment":154},{"nctId":"NCT00699517","phase":"PHASE3","title":"A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Sarcoma","enrollment":355},{"nctId":"NCT01263886","phase":"PHASE2","title":"Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-02","conditions":"Non-small Cell Lung Cancer","enrollment":176},{"nctId":"NCT01293630","phase":"PHASE1","title":"A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-01","conditions":"Advanced Solid Tumors","enrollment":18},{"nctId":"NCT01193595","phase":"PHASE1","title":"Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Neoplasms, Malignant","enrollment":39},{"nctId":"NCT00968916","phase":"PHASE1","title":"Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-09","conditions":"Solid Tumor","enrollment":15},{"nctId":"NCT01095302","phase":"PHASE1","title":"Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05","conditions":"Neoplasms, Malignant","enrollment":11},{"nctId":"NCT01907685","phase":"PHASE1","title":"Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Advanced Neoplastic Disease","enrollment":58},{"nctId":"NCT00719524","phase":"PHASE1","title":"AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Neoplasms","enrollment":71},{"nctId":"NCT01063946","phase":"PHASE1","title":"A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Neoplasms, Malignant","enrollment":3},{"nctId":"NCT01021150","phase":"PHASE1","title":"Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-03","conditions":"Neoplasms, Malignant","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ombrabulin (AVE8062)","genericName":"Ombrabulin (AVE8062)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ombrabulin is a vascular disrupting agent that binds to tubulin and disrupts microtubule dynamics, causing selective destruction of tumor vasculature and tumor cell death. Used for Non-small cell lung cancer (NSCLC), Ovarian cancer, Other solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}